Opendata, web and dolomites

INFarm SIGNED

A unique, interferon-based veterinary therapy to minimize antimicrobial overuse in cattle and tackle the societal global problem of antimicrobial resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 INFarm project word cloud

Explore the words cloud of the INFarm project. It provides you a very rough idea of what is the project "INFarm" about.

payments    million    hindering    immune    enormous    2050    strategy    cattle    minimize    anti    commercial    animals    largely    commercialization    volume    output    realizing    therapy    consolidated    thereby    risk    business    upfront    renounce    reduce    mis    antimicrobials    infections    clear    solutions    appropriate    antimicrobial    completing    global    prevent    solution    resistance    income    public    overuse    deal    receive    health    pharmaceutical    markets    farmers    affordable    mission    121    give    licensing    infective    77    chain    maximize    milestone    strengthen    sustainable    drugs    plan    return    company    commercialize    alternatives    humans    demand    94    farmpharma    abundant    perform    royalty    putting    respectively    chance    keep    addressable    billion    deaths    clinical    market    safe    viral    infrastructure    threat    total    bacterial    feasibility    interferon    interferox    lack    treat    pressure    optimal    amr    stimulating    ip    alternative    accounting    validation    healthy    livestock   

Project "INFarm" data sheet

The following table provides information about the project.

Coordinator
FARMPHARMA AB 

Organization address
address: VIRDINGS ALLE 32B
city: UPPSALA
postcode: 754 50
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.farmpharma.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FARMPHARMA AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The rise of antimicrobial resistance (AMR) is a major threat to global public health as it will cause 10 million deaths per year by 2050. The rise in AMR is largely driven by the abundant mis- and overuse of antimicrobial drugs in humans and animals. As such, there is a strong demand to reduce the use of antimicrobials in animals, putting cattle farmers under enormous pressure to change their current way of working. However, the lack of appropriate alternatives is hindering them to renounce from (over)using antimicrobials as their production output and income are at risk.

At FarmPharma, we are on the mission to provide effective, safe and affordable solutions to keep livestock animals healthy and well. To do so, we are developing InterferOx, an interferon-based, immune-stimulating, anti-infective therapy for cattle with the unique ability to treat AND prevent viral AND bacterial infections. InterferOx can thus minimize the use of antimicrobials in cattle by providing farmers an effective and sustainable alternative, thereby providing a solution for the rise in AMR.

The global market volume is 1.5 billion cattle, with our total addressable markets of Europe and US accounting for 121 and 94 million, respectively. With InterferOx, we respond to the trends and needs of our €1.7 billion target market: the cattle antimicrobials market. We aim to commercialize InterferOx via a licensing deal with a pharmaceutical company after completing clinical validation. In return, we will receive upfront, milestone and royalty payments with an estimated value of €77.8 million within the next 7 years.

To maximize our chance of realizing this promising future, we will perform a feasibility study, focusing on market analysis, commercialization strategy, IP strategy and value chain, to deliver a consolidated business plan. This will give us a clear understanding of the commercial potential of InterferOx, strengthen our current infrastructure, and define our optimal business strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More